COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Monika Gawalko*, Agnieszka Kaplon-Cieslicka, Mathias Hohl, Dobromir Dobrev, Dominik Linz

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

52 Citations (Web of Science)

Abstract

Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Original languageEnglish
Article number100631
Number of pages8
JournalIJC Heart & Vasculature
Volume30
DOIs
Publication statusPublished - Oct 2020

Keywords

  • ACE2
  • AMIODARONE
  • ARRHYTHMIAS
  • Anticoagulation
  • Arrhythmia
  • CRITICALLY-ILL PATIENTS
  • DISEASE
  • DYSFUNCTION
  • INFLAMMATION
  • Inflammasome
  • OBSTRUCTIVE RESPIRATORY EVENTS
  • OUTCOMES
  • PROMOTES
  • RECEPTOR
  • Remote monitoring
  • Thromboembolic risk
  • ACTIVATION

Cite this